顺铂腹腔灌注化疗联合静脉化疗治疗进展期胃肠道肿瘤近期疗效观察

为观察并评价顺铂(DDP)腹腔灌注化疗联合静脉化疗治疗进展期胃肠道肿瘤的近期疗效和不良反应,将54例进展期胃肠道肿瘤患者分成两组:单纯化疗组26例,其中胃癌14例采用HELF方案,大肠癌12例采用OLF方案;联合组28例,其中胃癌15例,大肠癌13例,先给予DDP腹腔灌注化疗,1周后加静脉化疗。静脉化疗方案同单纯化疗组。结果示,单纯化疗组CR1例,PR7例,NC10例,PD8例,有效率为30.8%(8/26);联合组CR2例,PR15例,NC7例,PD4例,有效率为60.7%(17/28)。治疗后的不良反应主要为消化系统毒性及骨髓抑制。初步研究结果提示,DDP腹腔灌注化疗联合静脉化疗治疗进展期胃肠道肿瘤近期疗效显著,值得临床研究。

Intraperitioneal perfusion chemotheraphy using cisplatin combined with intravenous chemotheraphy for patients with advanced gastrointestinal carcinoma

The objective of this sutdy was to evaluate the immediate clinical efficacy and toxicities of intraperitoneal perfusion chemotheraphy using cisplatin combined with intravenous chemotheraphy for patients with advanced gastrointestinal carcinoma. Fifty-four cases with advanced gastrointestinal carcinoma were divided into two groups. The Group 1 of 26 cases were treated with chemotherapy alone: HELF regimen for 14 advanced gastric cancer patients and OLF regiment for 12 advanced colorectal cancer patients. The Group 2 of 28 cases were treated with intraperitoneal chemotheraphy of cisplatin, after one week, they were treated with intravenous chemotherapy. Chemotheraphy regiment of Group 2 was the same as the Group 1. Drugs were repeated every 21 days and evaluated after 2-3 cycles. There were 1 CR, PR 7, NC 10, PD 8 in the chemotherapy alone group. The response rate was 30.8% (8/26). There were 2 CR, PR 15, NC 7, PD 4 in the combined chemotherapy group. The response rate was 60.7%(17/28). The major toxic and side effects were digestive tract reaction and myelosuppression. In conclusion, the combination of intrapentoneal perfusion chemotheraphy with cisplatin and intravenous chemotheraphy is effective for advanced gastrointestinal carcinoma and worthy to be further studied.